Bristol-Myers Squibb Company and WuXi PharmaTech announced that they have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications.
Ricerca Biosciences announced a strategic partnership with Fulcrum Pharma to provide value-added capabilities to biopharmaceutical companies by creating a streamlined and efficient process to move a candidate from development to clinical evaluation.
PharmaNet Development Group, Inc. announced the results from its fourth semi-annual industry survey on pharmaceutical observational research.
Frontage Laboratories, Inc., a provider of preclinical DMPK, CMC drug development and CTM manufacturing, bioanalytical, clinical and consulting services, has achieved AAALAC International accreditation.
DaVita Clinical Research (DCR), a provider of clinical research and diagnostic laboratory services, opened a central laboratory, expanded its health economics leadership, and participated in top renal industry meetings in 2010.
The addition of the USP 797 cleanroom to Celerion's Phase I core capabilities, enables sterile extemporaneous compounding in-house for microtracer studies, giving clients access to quality data earlier in drug development process.
Phenomenex Inc. introduces Easy Seal, an advanced seal for GC columns that addresses common problems with installation and reliability.
Accelrys, Inc., a scientific enterprise R&D software and services company, announced the release of the 6.6 version of Symyx Notebook by Accelrys.
Eppendorf announces that The Genome Center at Washington University has purchased and installed 10 additional epMotion 5075 TMX PC systems for its next-generation sequencing sample preparation needs on the Illumina GAIIx and HiSeq platforms.
Sucampo Pharmaceuticals Inc. reported a fourth-quarter loss on lower research and development revenue and higher costs. Revenue on fell on lower funding from partner Takeda after the company completed two late-stage studies on Amitiza.
New research has found that a cell-surface protein called CNT1, which transports cancer-killing drugs into tumor cells, was reduced in function in two thirds of pancreatic tumors.
New findings on how tuberculosis bacteria develop multi-drug tolerance point to ways TB infections might be cured more quickly. The results identify both a mechanism and a potential therapy for drug tolerance that is induced in the TB bacteria by the host cells they infect.
Gilead Sciences, Inc. announced that the Food and Drug Administration has approved a change to the prescribing information for Letairis, a once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension patients.
AstraZeneca PLC and Bristol-Myers Squibb Co. say their diabetes drug Onglyza has been approved in Europe for treating people with Type 2 diabetes who have moderate or severe renal impairment.
Somaxon Pharmaceuticals Inc. said its fourth-quarter net loss widened as the company boosted spending to promote the insomnia drug Silenor. Somaxon specializes in developing drugs that treat central nervous system disorders.